153 related articles for article (PubMed ID: 23001404)
1. Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response.
Kee KM; Wang JH; Hung CH; Chen CH; Lee CM; Lu SN
Dig Dis Sci; 2013 Feb; 58(2):556-61. PubMed ID: 23001404
[TBL] [Abstract][Full Text] [Related]
2. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
[TBL] [Abstract][Full Text] [Related]
3. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
4. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.
Cieśla A; Bociąga-Jasik M; Sobczyk-Krupiarz I; Głowacki MK; Owczarek D; Cibor D; Sanak M; Mach T
World J Gastroenterol; 2012 Sep; 18(35):4892-7. PubMed ID: 23002361
[TBL] [Abstract][Full Text] [Related]
5. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
6. Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C.
Jun BG; Park EJ; Lee WC; Jang JY; Jeong SW; Kim YD; Cheon GJ; Cho YS; Lee SH; Kim HS; Lee YN; Kim SG; Kim YS; Kim BS
Korean J Intern Med; 2019 Sep; 34(5):989-997. PubMed ID: 29529840
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.
Mira JA; Neukam K; López-Cortés LF; Rivero-Juárez A; Téllez F; Girón-González JA; de los Santos-Gil I; Ojeda-Burgos G; Merino D; Ríos-Villegas MJ; Collado A; Torres-Cornejo A; Macías J; Rivero A; Pérez-Pérez M; Pineda JA; ;
Eur J Clin Microbiol Infect Dis; 2015 Sep; 34(9):1879-84. PubMed ID: 26115631
[TBL] [Abstract][Full Text] [Related]
8. Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.
Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Okada K; Kainuma M; Kajiwara E; Takahashi K; Satoh T; Hayashi J
J Viral Hepat; 2013 Dec; 20(12):838-46. PubMed ID: 24304453
[TBL] [Abstract][Full Text] [Related]
9. A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia.
Tahara H; Takagi H; Sato K; Shimada Y; Tojima H; Hirokawa T; Ohyama T; Horiuchi K; Naganuma A; Arai H; Kakizaki S; Mori M
J Gastroenterol; 2011 Aug; 46(8):1010-9. PubMed ID: 21594564
[TBL] [Abstract][Full Text] [Related]
10. Prognostic effect of response to interferon therapy after laparoscopic splenectomy among patients with marked thrombocytopenia and hepatitis C virus-related cirrhosis.
Tamai H; Mori Y; Shingaki N; Shimizu R; Nuta J; Moribata K; Maeda Y; Muraki Y; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Takifuji K; Yamaue H; Ichinose M
Hepatol Int; 2015 Jan; 9(1):67-75. PubMed ID: 25788381
[TBL] [Abstract][Full Text] [Related]
11. Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy.
Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Dai CY; Huang JF; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2018 May; 33(5):1108-1114. PubMed ID: 29023927
[TBL] [Abstract][Full Text] [Related]
12. Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: a prospective study.
Kee KM; Wang JH; Hung CH; Chen CH; Lee CM; Chang KC; Tseng PL; Yen YH; Lin CY; Lu SN
J Gastroenterol Hepatol; 2012 Jun; 27(6):1106-11. PubMed ID: 22004331
[TBL] [Abstract][Full Text] [Related]
13. Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia.
Hofer H; Gurguta C; Bergholz U; Steindl-Munda P; Ferenci P
Wien Klin Wochenschr; 2006 Oct; 118(19-20):595-600. PubMed ID: 17136334
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.
Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Akahoshi T; Maehara Y; Hayashi J;
J Gastroenterol Hepatol; 2014 Sep; 29(9):1728-35. PubMed ID: 24731162
[TBL] [Abstract][Full Text] [Related]
15. Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts.
Lin KH; Hsu PI; Yu HC; Lin CK; Tsai WL; Chen WC; Chan HH; Lai KH
BMC Gastroenterol; 2012 Jan; 12():7. PubMed ID: 22257364
[TBL] [Abstract][Full Text] [Related]
16. Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C.
Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():327-34. PubMed ID: 27051280
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
Cordero-Ruiz P; Carmona-Soria I; Rodríguez-Téllez M; Caunedo-Alvarez A; Quezada-Pacheco RH; Flores-Cucho A; Romero-Gómez M; Vilches-Arenas Á
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):792-799. PubMed ID: 28445251
[TBL] [Abstract][Full Text] [Related]
18. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
Everson GT; Hoefs JC; Seeff LB; Bonkovsky HL; Naishadham D; Shiffman ML; Kahn JA; Lok AS; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Morishima C;
Hepatology; 2006 Dec; 44(6):1675-84. PubMed ID: 17133499
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy.
Koh C; Heller T; Haynes-Williams V; Hara K; Zhao X; Feld JJ; Kleiner DE; Rotman Y; Ghany MG; Liang TJ; Hoofnagle JH
Aliment Pharmacol Ther; 2013 May; 37(9):887-94. PubMed ID: 23461575
[TBL] [Abstract][Full Text] [Related]
20. [A clinical study of antiviral therapy for patients with compensated hepatitis C cirrhosis].
Xie ZW; Li JP; Guan YJ; Zhang XY; Guo FX; Chen BB; Pan CQ
Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):827-833. PubMed ID: 29325276
[No Abstract] [Full Text] [Related]
[Next] [New Search]
